جست‌وجوی استاد و پژوهشگر

Bradley E. Aouizeratمشاهده پروفایل

استاد

• Oral-Systemic Health
• Genomics
• Epigenetics
• +۱۲ مورد دیگر

Bradley E. Aouizerat is a Professor at the College of Dentistry, New York University (NYU) , with a strong focus on oral-systemic health, genomics, and translational research. His work bridges dentistry, immunology, and chronic disease, particularly in populations affected by HIV, cancer, and health disparities. Education: BS in Microbiology/Molecular Genetics – University of California at Los Angeles PhD in Microbiology/Molecular Genetics/Immunology – University of California at Los Angeles MAS in Master of Advanced Science Research in Clinical – University of California at San Francisco His research interests span epigenetics, gene expression, pain mechanisms, microbiome, sleep, and inflammation , with a strong emphasis on biomarker discovery and minority health. He has led studies on DNA methylation in oral cancer, cytokine profiles in HIV, and the role of mitochondrial genetics in diabetes. His work often integrates machine learning and longitudinal cohort data from major studies like the Women’s Interagency HIV Study (WIHS) and Multicenter AIDS Cohort Study (MACS). His recent publications (2021–2025) reflect a broad and impactful research program, with studies in oral cancer, HIV persistence, depression in chronic disease, lymphedema, sleep disruption, and gut microbiota . These works highlight his interdisciplinary approach, combining molecular biology with clinical epidemiology and behavioral science. Key themes include epigenetic regulation of pain and opioid tolerance, neurodegenerative-like changes in cancer, and social determinants of inflammation . Scientific Awards and Recognition: Excellence in Research Mentoring Faculty Teaching Award (2013) Most Dedicated Mentor Award, PMCTR Fellowship Program (2009) Early Career Investigator Award, Bayer Healthcare International (2006) National Liver Scholar Award, American Liver Foundation (2004) Multiple early career and mentoring recognitions (2004–2006) He is an active mentor and collaborator , frequently co-authoring with junior researchers and leading interdisciplinary teams. His work has been supported by NIH-funded initiatives, including the Roadmap K12 program. He is a member of professional societies such as the American Heart Association, American Liver Foundation, and American Society for Human Genetics . He is involved in clinical and translational research teams focused on improving outcomes in cancer, HIV, and chronic pain. His lab and collaborators utilize advanced genomic and bioinformatic tools to uncover mechanisms linking biological systems with patient-reported outcomes. Future work is likely to expand on precision biomarkers, minority stress interventions, and real-time symptom detection using machine learning .

Tony Tiganisمشاهده پروفایل

استاد

• Cell Signalling
• Protein Tyrosine Phosphatases (PTPs)
• Obesity
• +۱۲ مورد دیگر

Tony Tiganis is a Professor in the Department of Biochemistry and Molecular Biology at Monash University, where he also serves as Laboratory Head and leads the Metabolism, Diabetes and Obesity Program at the Monash Biomedicine Discovery Institute. He holds a joint appointment as Laboratory Head at the Peter MacCallum Cancer Centre and is an Adjunct Professor at Yale School of Medicine. His multidisciplinary research focuses on protein-tyrosine-phosphatases (PTPs) and their roles in metabolism, cancer, and immunity. Ph.D. in Biochemistry, University of Melbourne (1990–1994) B.Sc. (Hons) in Pharmacology, University of Melbourne (1986–1989) Professor Tiganis’s research centers on tyrosine-phosphorylation-dependent signaling, with a focus on PTPs. His work has challenged long-standing misconceptions about PTPs being 'undruggable' and has revealed their critical roles in obesity, type 2 diabetes, cancer, and immune regulation. His lab has made seminal contributions to understanding redox balance in metabolic health, T cell tolerance mechanisms, and central control of energy balance. These discoveries have significant translational potential, including intranasal therapies for obesity and genetically engineered CAR T cells for solid tumors. His recent publications span high-impact journals such as Journal of Clinical Investigation , Nature Communications , and Cell Metabolism , highlighting trends in redox signaling, immunometabolism, and therapeutic targeting of PTPs in cancer and metabolic disease. His work is frequently cited and has garnered attention from news outlets, social media, and the pharmaceutical industry. Melbourne University Postgraduate Scholarship (1990) C.J. Martin Fellowship, NHMRC (1995) AMRAD Post-Doctoral Award (1998) St. Vincent’s Hospital Research Week, Senior Investigator Prize (1999) Deans Award in Excellence in Research (2009) NHMRC Principal Research Fellowships (2010–2015, 2016–2020) Tony Tiganis actively supervises PhD students and leads multiple research projects funded by the National Breast Cancer Foundation and Cancer Council Victoria. He serves as an editor for FEBS Journal , Molecular & Cellular Biology , and Science Advances . His lab operates the Monash Metabolic Phenotyping Facility and collaborates with clinicians and chemists on translational programs. He is also a Scientific Advisory Board Member at DepYmed Inc. and a Consultant for Regeneron Pharmaceuticals. He leads a multidisciplinary team exploring the intersection of metabolism, immunity, and cancer, with ongoing projects investigating the impact of obesity on anti-tumor immunity and phosphatase roles in cancer pathogenesis.

Sharon L.R. Kardiaمشاهده پروفایل

استاد

• Genetic Epidemiology
• Cardiovascular Disease
• Gene-Environment Interactions
• +۳ مورد دیگر

Sharon L.R. Kardia is the Millicent W. Higgins Collegiate Professor of Epidemiology and Associate Dean for Education at the University of Michigan School of Public Health (SPH). She holds a PhD in Human Genetics (1991) and MA in Statistics (1990), both from the University of Michigan. Her research focuses on genetic epidemiology of chronic diseases, particularly cardiovascular conditions, emphasizing gene-environment and gene-gene interactions. She directs the Public Health Genetics Program and co-directs the Life Sciences and Society Program and the Michigan Center for Genomics and Public Health. Education: PhD in Human Genetics (University of Michigan, 1991); MA in Statistics (University of Michigan, 1990). Postdoctoral training in systems biology at the Department of Microbiology and Immunology. Research Interests: Genetic epidemiology of cardiovascular diseases, chronic disease prevention, genomic/epigenomic analyses in large cohorts, and translational public health genetics. Notable Projects: Co-leads initiatives integrating genomics with public health practice, including the Michigan Center for Genomics and Public Health. Her work spans population studies, analytical method development, and interdisciplinary program leadership. Labs/Teams: Public Health Genetics Program, Life Sciences and Society Program. Teaches courses on AI in public health (PUBHLTH555) and integrative learning experiences for MPH students (PUBHLTH680).

Jukka Alinikulaمشاهده پروفایل

استاد مدعو

• Immunology
• B lymphocytes
• Somatic hypermutation
• +۴ مورد دیگر

Jukka Alinikula is an Adjunct Professor at the University of Turku's Institute of Biomedicine, specifically within the Unit of Infection and Immunity. He also serves as a University Lecturer in immunology and drug development, and as the Education Director of the Immudocs program. His research focuses on somatic hypermutation mechanisms in B lymphocytes, exploring how antibody diversity is generated while avoiding oncogenic mutations. Alinikula completed his PhD at the University of Turku (Lassila Lab), followed by a postdoc at Yale University (Schatz Lab). Research Interests: Alinikula’s work investigates the targeting of somatic hypermutation to immunoglobulin genes versus proto-oncogenes. His lab uses modern techniques like reporter assays, CRISPR-based screens, and single-cell transcriptomics to dissect mutation enhancer functions. Key topics include genome stability, lymphoma etiology, and the interplay between antibody diversification and cancer risk. Teaching: He teaches immunology and immunopharmacology across bachelor’s, master’s, medical, and doctoral programs, emphasizing case-based learning and practical laboratory training. Supervised students include PhD candidates in immunology and drug development. Labs/Teams: Leads his own research group at the Institute of Biomedicine, collaborating extensively with international teams (e.g., Yale, Czech Academy of Sciences). Active in the InFLAMES Flagship initiative for immune system research.

Stephen C. Bergmeierمشاهده پروفایل

استاد

• Medicinal Chemistry
• Organic Synthesis
• Heterocyclic Chemistry
• +۷ مورد دیگر

Stephen C. Bergmeier is a Professor in the Department of Chemistry and Biochemistry within the College of Arts and Sciences at Ohio University. His research bridges synthetic organic chemistry and biological applications, with a focus on developing novel therapeutic strategies for cancer and infectious diseases. Research Interests: His work spans three primary areas: (1) Design of glucose uptake inhibitors as anticancer agents, targeting cancer metabolism; (2) Development of small molecules that modulate RNA transcription via T-box riboswitches, offering new antibacterial strategies; and (3) Synthetic methodology involving strained heterocycles like aziridines for constructing complex nitrogen-containing ring systems. These projects highlight the synergy between method development and drug discovery. Publication Trends: His recent publications (2010–2017) reflect a consistent focus on heterocyclic synthesis, mechanism-driven drug design, and chemical biology. The articles reveal an interdisciplinary approach combining organic synthesis, molecular modeling, and biological evaluation, particularly in targeting metabolic pathways and RNA structures in disease. Scientific Awards: No awards are listed in the provided text. Advising and Grants: While specific students and grant funding are not mentioned, Dr. Bergmeier leads an active research group with collaborative projects involving Prof. X. Chen (cancer metabolism) and Prof. J. V. Hines (RNA biology), suggesting external funding and mentorship of graduate students and researchers. Labs and Teams: His research is conducted at Ohio University’s Athens Campus in the Chemistry and Biochemistry department, likely involving a research group focused on synthetic and medicinal chemistry. The work is collaborative and integrates organic synthesis with biochemical and cellular assays.

Andreas Stadlbauerمشاهده پروفایل

استاد مدعو

• Biomedical Imaging
• Medical Physics
• Artificial Intelligence in Medicine
• +۷ مورد دیگر

Prof. Dr. Andreas Stadlbauer is a medical physicist affiliated with the Clinical Institute for Diagnostic and Interventional Radiology at St. Pölten University Hospital and the Department of Neurosurgery at Friedrich-Alexander University Erlangen-Nuremberg. He holds an adjunct professorship at the University of Erlangen-Nuremberg and contributes to both clinical and academic research in biomedical imaging and AI applications in oncology. University: Friedrich-Alexander University Erlangen-Nuremberg Hospital Affiliation: St. Pölten University Hospital Department: Department of Neurosurgery Academic Rank: Adjunct Professor His research focuses on advanced MRI techniques, particularly physio-metabolic imaging of brain tumors, oxygen metabolism, and the integration of artificial intelligence in clinical diagnostics. He has led research on glioma classification, tumor microenvironment characterization, and deep learning models for radiomic analysis. The recent publications highlight a strong trend toward AI-driven diagnostic tools in neuro-oncology, particularly in differentiating glioblastomas from metastases and predicting genetic mutations using machine learning. His work emphasizes the clinical translation of complex imaging data into actionable insights. Artificial Intelligence in Oncology Medical Imaging and Radiomics Brain Tumor Metabolism Deep Learning for MRI Analysis Oxygen Metabolism Imaging Clinical Decision Support Systems Prof. Stadlbauer has been involved in seed-funded research projects developing deep learning algorithms for clinical integration. He collaborates extensively with neurosurgeons, radiologists, and oncologists across institutions, contributing to multidisciplinary tumor boards and translational research initiatives. He completed his doctorate in medical physics in 2004, habilitation in 2008, and an MBA in Health Management in 2010. His academic journey reflects a blend of technical expertise and leadership in healthcare innovation.

John M. Streicherمشاهده پروفایل

استاد

• Molecular Pharmacology
• Opioid Receptor Signaling
• Chronic Pain Research
• +۳ مورد دیگر

John M. Streicher is a Professor in the Graduate College of the University of Arizona, holding appointments in both the Neuroscience Graduate Interdisciplinary Program (GIDP) and Pharmacology. His research focuses on molecular signal transduction cascades related to opioid, adenosine, and orphan receptors in chronic pain. BS: George Fox University, 1999 MS: Oregon Health and Science University, 2002 PhD: University of California – Los Angeles, 2009 Research interests center on identifying new signaling regulators of opioid receptors, determining their molecular mechanisms, and translating these findings into novel painkiller development without side effects like addiction. His methodologies include CRISPR/Cas9 gene editing in mice, high-throughput drug screening, and creating pain state models (e.g., post-surgical pain). His publications from 2023–2002 span opioid receptor pharmacology, pain pathway modulation, ion channel inhibition, and drug design strategies (e.g., biased signaling, sulfonamide constraints). Articles frequently address chronic pain models, receptor-specific ligands, and neuroinflammatory mechanisms. Cover selection for Science Signaling (2023, 2020) INRC Young Investigator Award (2022) UA Undergraduate Biology Research Program Outstanding Faculty Mentor Award (2020-2021) Cyagen Animal Model Award (2017) ASPET Young Scientist Travel Award (2011) Dr. Streicher's work bridges molecular pharmacology and translational pain research, with a focus on developing next-generation analgesics through innovative biochemical and genetic approaches.

• Global Oncology
• Prostate Cancer
• Bladder and Kidney Cancer
• +۷ مورد دیگر

Priti Lal, MD, is an Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine. She serves as the Director of GU Pathology and is an Associate Scholar at the Center for Global Health. Her work bridges advanced pathology, AI-driven diagnostics, and global oncology, with a strong focus on improving cancer outcomes for men of African descent. Her research interests lie at the intersection of global oncology , medical education , and digital pathology . She specializes in bladder, kidney, and prostate cancers, applying cutting-edge computational image analysis to develop nondestructive, AI-based prognostic tools such as Histotyping and AAstro . These innovations aim to address disparities in prostate cancer outcomes by creating population-specific models for African American and African men. The recent publications highlight a strong trend in leveraging AI and genomics to uncover biologically distinct cancer pathways and improve risk stratification. Her work emphasizes stromal morphology and gland structure in prognostication, moving beyond traditional clinical parameters to enhance accuracy. Scientific recognition includes: Co-inventor of US Patent US20210035694A1 for an AI-derived stromal signature in prostate cancer Dr. Lal is deeply involved in global health mentorship, particularly through the MADCAP consortium—a collaborative network involving Harvard, Moffit, Penn, and ten African countries. She mentors students and trainees from Africa, promoting capacity building in molecular diagnostics and pathology education. While specific grant details are not listed, her leadership in international research initiatives suggests active grant-supported work. She leads pathology innovation at Penn and is a key figure in the MADCAP consortium, driving collaborative research and education across continents. Her lab focuses on translating AI-based image analysis into clinical tools for equitable cancer care.

Ted Huppمشاهده پروفایل

استاد

• Cancer Research
• p53 Pathway Science
• Protein-Protein Interactions
• +۷ مورد دیگر

Ted Hupp is Chair of Cancer Research and Professor of Cancer Research at the University of Edinburgh's Institute of Genetics and Cancer, where he leads the Edinburgh Cancer Research Centre. His laboratory focuses on developing next-generation technologies for drug discovery in cancer, with particular emphasis on cancers of unmet clinical need including oesophageal adenocarcinoma and sarcomas. Dr. Hupp's research interests center on understanding cancer progression pathways, particularly those involving p53 mutation, which is one of the most common genetic changes in cancer development. His lab employs biophysical, biochemical, and proteomic approaches to develop novel molecular insights into clinically relevant cancer progression pathways. His work spans three main research programs: drugging protein-protein interactions to activate the p53 tumour suppressor, investigating the secretory pathway as a driver in oesophageal cancer, and developing immunotherapeutics, monoclonal antibodies, and vaccinology platforms. Analysis of his recent publications reveals a strong focus on proteogenomics, protein science, and translational applications. His work increasingly integrates canine models for comparative medicine, proteomic approaches to understand protein synthesis dynamics, and novel antibody development for cancer therapeutics. The research shows a clear trajectory toward personalized cancer immunotherapies and vaccine development based on neoantigen landscapes. Professor Hupp has successfully secured funding from major organizations including BBSRC, Medical Research Scotland, The Technology Strategy Board, British Council, European Union Development Fund, Wellcome Trust, and Cancer Research UK. His current projects include optimization of synthetic antibody libraries, selection and characterization of anti-peptide synthetic antibodies, CRISPR-based genome-wide approaches for identifying vulnerabilities in canine oral melanoma, and the KATY project focused on clinical knowledge systems. He advises multiple PhD students including Kamila Pawlicka, Estefania Esposito, Vanessza Fentor, Sinem Gul, and Mishal Tariq. His research group collaborates extensively with scientists across the University of Edinburgh, Cambridge University, Masaryk Cancer Institute in Brno, and the Indian Institute for Science in Bangalore. The lab maintains expertise in protein science, post-translational modifications, phage antibody libraries, RNA editing, p53 pathway science, and proteogenomics.

• Eukaryotic RNA processing
• Post-transcriptional gene regulation
• Spliceosome structure and mechanism
• +۶ مورد دیگر

Melissa J. Moore, PhD, is Professor at the University of Massachusetts Chan Medical School, where she holds the Eleanor Eustis Farrington Chair of Cancer Research and serves in the RNA Therapeutics Institute. She also holds appointments in the T. H. Chan School of Medicine (Department of Chemical Biology) and the Morningside Graduate School of Biomedical Sciences (Departments of Biochemistry & Molecular Biotechnology, Interdisciplinary Graduate Program, and Translational Science). Additional affiliations include campus-wide programs in Bioinformatics & Integrative Biology and Chemical Biology. Education: BS in Chemistry/Biology, College of William and Mary PhD in Biological Chemistry, Massachusetts Institute of Technology Research Focus: Melissa Moore’s laboratory investigates post-transcriptional gene regulation in eukaryotes, with emphasis on three interconnected themes: (1) spliceosome structure and catalytic mechanism, (2) nuclear-to-cytoplasmic control of mRNA metabolism, and (3) quality control and clearance of defective ribosomal and messenger RNAs. The group combines biochemistry, single-molecule biophysics, RNA structural biology, and cell biology to dissect these processes at molecular and systems levels. Scientific Awards & Honors: Eleanor Eustis Farrington Chair of Cancer Research Funding & Collaborations: Work is supported by grants from the National Institutes of Health and involves ongoing collaborations with investigators at Brandeis University, MIT, University of Rochester, and other institutions. Rotation projects for graduate students are available in all active research areas. Laboratory & Team: The Moore laboratory is located in the RNA Therapeutics Institute at UMass Chan Medical School, 364 Plantation Street, Worcester, MA. The team employs state-of-the-art single-molecule imaging, mass spectrometry, and high-throughput sequencing to advance understanding of RNA biology and to translate insights into therapeutic RNA technologies.

Jianjun Chenمشاهده پروفایل

استاد

• RNA Epigenetics
• DNA Epigenetics
• Cancer Biology
• +۷ مورد دیگر

Jianjun Chen, Ph.D. serves as Professor and Chair of the Department of Systems Biology and Director of the Center for RNA Biology and Therapeutics at City of Hope's Beckman Research Institute. Appointed Chair in August 2020, he previously served as Professor and Vice Chair from 2017-2020. He also holds the Simms/Mann Family Foundation Chair in Systems Biology since 2018. Dr. Chen's research focuses on RNA and DNA epigenetic mechanisms in cancer development and therapy resistance. His laboratory has made seminal contributions to understanding RNA modifications including N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), and 7-methylguanosine (m⁷G), and their roles in cancer initiation, progression, drug resistance, and immune evasion. The lab also studies DNA epigenetic regulation through TET proteins and develops novel therapeutic strategies targeting epigenetic regulators. His recent publications reveal trends in RNA epigenetics, cancer metabolism, immune evasion mechanisms, and therapeutic targeting of epigenetic regulators. His work spans multiple cancer types including leukemia, lymphoma, and solid tumors, with emphasis on translating basic discoveries into clinical applications. Research Scholar of the American Cancer Society (2011) Scholar of The Leukemia & Lymphoma Society (2017) Researcher of the Year, The Pamela B. Katten Memorial Leukemia Research Foundation Award (2014) The Leukemia & Lymphoma Society Scholar CDP Achievement Award (2022) Fellow of the American Association for the Advancement of Science (AAAS) (2023) Dr. Chen's research program is supported by multiple R01 grants from the National Cancer Institute. His laboratory actively mentors researchers and has developed several small-molecule inhibitors with strong therapeutic potential in preclinical models. The Chen Laboratory is dedicated to translating fundamental discoveries in RNA and DNA epigenetics into effective clinical therapies for cancer patients. The laboratory operates within City of Hope's comprehensive cancer center, collaborating with clinical teams to bridge basic research and patient care. Current projects focus on developing prognostic systems for cancer risk stratification and creating targeted therapeutic strategies that inhibit aberrant epigenetic regulators such as FTO, IGF2BP2, YTHDF2, METTL16, and TET1.

• Plasma Medicine
• Reactive Oxygen and Nitrogen Species (RONS)
• Cancer Therapy
• +۳ مورد دیگر

Dr. Endre J Szili is an Adjunct Senior Research Fellow at the Future Industries Institute, University of South Australia. His work bridges plasma physics, biomedical engineering, and cancer therapy through the development of cold plasma technologies for medical applications. Research focus on reactive oxygen and nitrogen species (RONS) in cancer treatment, wound healing, and biomaterials modification. Collaborates with institutions including the University of Adelaide, Osaka Metropolitan University, and University of Sheffield. Research interests center on cold atmospheric pressure plasma for biomedical solutions, with key contributions to plasma-activated media (PAM) as a novel therapeutic strategy for ovarian cancer and chronic wound infections. His studies explore RONS generation, tissue penetration mechanisms, and plasma jet optimization for controlled delivery of reactive species. Recent work highlights plasma medicine trends, including applications in antimicrobial therapy via plasma-activated hydrogel (PAHT) and computational modeling of plasma streamers for medical device innovation. Articles emphasize oxidative stress pathways, biofilm disruption, and tailored plasma protocols for clinical translation. Grants include Australian Research Council Future Fellowship FT190100263 and NHMRC Grant 2002510, supporting advancements in plasma technology for oncology and infection control. His interdisciplinary collaborations span physics, engineering, and clinical medicine.

• Vascular Access
• Cannulation
• Rectum Cancer
• +۵ مورد دیگر

Harm J. Scholten serves as a University Researcher at Eindhoven University of Technology (TU/e), specifically within the Signal Processing Systems group of the Electrical Engineering department. He maintains a dual affiliation with Catharina Hospital, where he applies engineering principles to clinical medical challenges. His research profile shows strong connections to the Eindhoven MedTech Innovation Center, reflecting his interdisciplinary focus on medical technology development. Dr. Scholten's research spans multiple critical medical domains with particular emphasis on ultrasound guidance applications in clinical settings. His work in vascular access (100% research focus), cannulation techniques (93%), and rectal cancer treatment (85%) demonstrates a clear trajectory in developing and validating medical technologies for surgical and intensive care applications. The fingerprint analysis of his publications reveals additional significant contributions to total mesorectal excision procedures (56%), critical care medicine (56%), and arm-related vascular procedures (51%). Analysis of his recent publications (2021-2023) reveals a consistent theme of applying advanced imaging technologies to improve procedural outcomes in vascular access, critical care, and oncological surgery. His work bridges engineering and clinical medicine, with particular focus on 3D ultrasound applications, fluid management protocols in ICUs, and enhanced recovery pathways for cancer patients. The research demonstrates strong clinical validation through multiple randomized controlled trials and feasibility studies. Dr. Scholten has established productive collaborations across multiple institutions, with particular emphasis on the Catharina Hospital partnership. His research contributes to UN Sustainable Development Goals related to health and well-being, focusing on improving medical procedures and patient outcomes through technological innovation.

• Immunology
• Molecular Immunology
• T cell biology
• +۵ مورد دیگر

Brigitta Stockinger is a distinguished Professor at the Francis Crick Institute, leading research in the Division of Molecular Immunology. With a career spanning over three decades, she has established herself as a leading authority in immunology, particularly in the study of T cell biology and the aryl hydrocarbon receptor (AHR) pathway. PhD in Biology from the University of Mainz Postdoctoral training in London, Cambridge, and Heidelberg Member of the Basel Institute for Immunology (1985-1991) Group leader at MRC National Institute for Medical Research (1991-present, now part of Francis Crick Institute) Head of Division of Molecular Immunology (2010-present) Professor Stockinger's research has evolved from studying immune tolerance using T cell receptor transgenic mouse models to pioneering work on immunological memory with CD4 memory T cells. Her lab made seminal discoveries regarding Th17 cell differentiation factors, which led to groundbreaking research on the aryl hydrocarbon receptor (AHR) as an environmental sensor in the immune system. Her work spans fundamental immunology, infection responses, inflammation, and the intersection of environmental factors with immune regulation. Analysis of her extensive publication record (over 65 Crick publications) reveals a strong focus on Immunology (38 publications), followed by Model Organisms (12), Genetics & Genomics (10), and Tumour Biology (9). Her most influential work appears in top journals including Nature (5 papers), Nature Immunology (6 papers), and Immunity (6 papers), demonstrating the high impact of her research on understanding T cell plasticity, AHR signaling, and mucosal immunity. Fellow of the Academy of Medical Sciences (2005) EMBO fellow (2008) Fellow of the Royal Society (2013) ERC Advanced Investigator grant (2009) Wellcome Senior Investigator Grant (2013) CRUK grant (2015) Wellcome Investigator Grant (2018) Professor Stockinger's laboratory investigates how environmental factors influence immune responses through the AHR pathway, with particular emphasis on intestinal immunity, inflammation, and host-microbe interactions. Her work has significant implications for understanding inflammatory bowel diseases, infection responses, and the role of dietary components in immune regulation. She has established numerous collaborations across the Francis Crick Institute and maintains active research programs examining AHR's role in both innate and adaptive immunity.

Shweta U. Dharمشاهده پروفایل

استاد

• Adult Genetics
• Cancer Genetics
• Genetic Disorders
• +۲ مورد دیگر

Shweta U. Dhar, MD, MS, FACMG, FACP, is a Professor and Medical Director of Adult Genetics at Baylor College of Medicine (BCM) in Houston, TX. She serves as Section Chief of Genetics at the Michael E. DeBakey VA Medical Center and is a member of the Dan L Duncan Comprehensive Cancer Center. She holds certifications from the American Board of Internal Medicine and American Board of Medical Genetics. Education includes: MBBS from NHL Municipal Medical College, Ahmedabad, India (1997) Residency in Pathology & Microbiology at Gujarat Cancer Research Institute (1999) MS in Biotechnology from Stephen F Austin State University, TX (2001) Internal Medicine Residency at New York INF Beekman Downtown Hospital (2006) Medical Genetics Fellowship at Baylor College of Medicine (2008) Her research focuses on diagnosis and management of adult genetic conditions, including: Single-gene disorders, chromosomal abnormalities, and familial cancer syndromes Cancer risk assessment and reproductive genetics Medical education innovation in genetics/genomics Healthcare delivery models for complex genetic conditions She directs BCM's Genetics course and founded the Genetics & Genomics Pathway for medical students. Recent publications demonstrate strong focus on clinical applications of genetics in neurodevelopmental disorders (Alexander disease, autism), cancer risk management (BRCA1, retinoblastoma), and healthcare system improvements. Her work frequently spans neurogenetics, cancer genetics, and medical education. Awards and honors: Fulbright & Jaworski Teaching & Evaluation Award (2013) Rising Star Clinician Award (2014) Fulbright & Jaworski Educational Leadership Award Clark Faculty Service Award (2018) Women of Excellence Award (2020) As Chair of the ACMG Adult Genetics Special Interest Group, she launched the Adult & Cancer Diagnostic Dilemmas session at national meetings. She serves on the ACMG Board of Directors as Clinical Director and leads clinical operations across BCM, VA, and Harris Health System genetics clinics.